Ovarian Cancer – Pipeline Insights, 2016 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Ovarian
Cancer-Pipeline Insights, 2016”
report to their offering.

The report provides comprehensive insights about pipeline drugs across
this indication. A key objective of the report is to establish the
understanding for all the pipeline drugs that fall under the category of
Ovarian Cancer. Ovarian cancer is the sudden growth of the cells in the
ovary and is a type of cancer that affects females only. The cancer
forms in tissues of the ovary when normal cells are affected. It can
affect either one or both the ovaries.

It is estimated that every year approximately 21,000 women in the USA
and 5,500 women in the UK are diagnosed with ovarian cancer. It is the
eighth most common cancer among women in the USA and fifth most common
cancer among females in the UK. The report provides in-depth analysis of
the pipeline assets across Ovarian Cancer. The Report gives insights on
225+ products. It also includes around 185+ companies which are active
in this field.

Companies Mentioned:

  • AbbVie Inc.
  • Oasmia Pharmaceutical AB
  • Merck KGaA
  • Novartis Pharmaceuticals
  • Baxter Oncology
  • Medison Pharma
  • Orion Pharmaceuticals
  • Merck KGaA

Key Topics Covered:

  1. Ovarian Cancer Overview
  2. Signs and symptoms
  3. Diagnosis
  4. Treatment
  5. Pipeline Therapeutics
  6. Therapeutics under Development by Companies
  7. Last Stage Products (Phase III)
  8. Comparative Analysis
  9. Mid Stage Products (Phase II)
  10. Comparative Analysis
  11. Early Stage Products (Phase I and IND)
  12. Comparative Analysis
  13. Discovery and Pre-clinical stage Products
  14. Comparative Analysis
  15. Therapeutic Assessment
  16. Assessment by Monotherapy Products
  17. Assessment by Combination Products
  18. Assessment by Route of Administration
  19. Assessment by Stage and Route of Administration
  20. Assessment by Molecule Type
  21. Assessment by Stage and Molecule Type
  22. Dormant Products
  23. Comparative Analysis
  24. Discontinued Products
  25. Comparative Analysis
  26. Appendix

For more information visit http://www.researchandmarkets.com/research/8nczdb/ovarian.


Research and Markets
Laura Wood, Senior Manager
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women’s
, Ovarian
Cancer Drugs